News for AxoGen, Inc. (0HKD.L)

Full Year 2024 Revenue: USD 187.3 million, a 17.8% increase compared to 2023.Fourth Quarter 2024 Revenue: USD 49.4 million, up 15.1% compared to the prior year

Feb 25, 2025 / 01:00PM GMTOperator Good morning everyone. Joining me on today's call is Michael Dale, AxoGen's Chief Executive Officer and director, and Nir Nao

Axogen, Inc. (NASDAQ:AXGN) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ETCompany ParticipantsMichael Dale - Chairman and Chief Executive...

Quarterly Revenue: $49.4 million, surpassing the estimated $48.57 million and marking a 15.1% increase from the same quarter last year.Quarterly EPS: $0.01, ex

ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. ( AXGN), a global leader in developing and marketing innovative surgical solutio

Transaction Overview On December 31, 2024, First Light Asset Management, LLC (Trades, Portfolio) executed a significant reduction in its holdings of KORU Medica

**media[538156]**

On December 31, 2024, First Light Asset Management, LLC (Trades, Portfolio) made a significant move by acquiring an additional 2,851,982 shares of Health Cataly

ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. ( AXGN), a global leader in developing and marketing innovative surgical solutio

Axogen stock soars to 52-week high, touches $18.99

AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Axogen stock soars to 52-week high, hits $17.24

ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. ( AXGN), a global leader in developing and marketing innovative surgical solutio

On December 31, 2024, First Light Asset Management, LLC (Trades, Portfolio) executed a notable transaction involving Axogen Inc. The firm added 260,822 shares t

Overview of Recent Transaction On October 31, 2024, First Light Asset Management, LLC (Trades, Portfolio) executed a significant transaction by adding 1,020,825

BioStem has enjoyed exceptional growth in its first year as a public company, with revenues soaring. Read why I think BSEM stock is a strong buy.

The growth of the Nerve Repair and Regeneration Market is propelled by continuous advancements in medical technology. Innovative surgical techniques and...

/PRNewswire/ -- DelveInsight's Nerve Repair and Regeneration Market Insights report provides the current and forecast market analysis, individual leading nerve...